Found 2491 clinical trials
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA) - Virtual
225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it.Participants will take BIIB122 or placebo 1 time a day for up
- 287 views
- 27 Apr, 2023
- 1 location
- Online study
A Trial Evaluating Different Dosing Durations of TEPEZZA® Treatment in Patients with Thyroid Eye Disease (TED)
The overall objective is to investigate the safety, tolerability and need for re-treatment of 3 different TEPEZZA® treatment durations (4, 8, or 16 infusions) in patients with TED.
- 29 views
- 13 Oct, 2022
- 14 locations
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)
The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …
- 10 views
- 18 Oct, 2022
- 53 locations
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.
- 3 views
- 06 Apr, 2023
- 67 locations
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The goal is to determine the efficacy, safety and tolerability for 300 patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)), or a placebo regimen for 52 weeks.Participants who complete all study visits may …
- 16 views
- 19 Dec, 2022
- 85 locations
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule. With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will
- 182 views
- 19 Dec, 2022
- 35 locations
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderateAlzheimer's Disease (AD).
- 0 views
- 08 Apr, 2023
- 7 locations
Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- 133 views
- 22 Feb, 2019
- 1 location
Ascend-Nash: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Crv431 In Adult Subjects With Nonalcoholic Steatohepatitis And Advanced Liver Fibrosis
Objectives:Primary: To evaluate the efficacy and safety of once daily (QD) 75 mg, 150 mg, and 225 mg doses of Rencofilstat compared to placebo control in subjects with
- 0 views
- 29 Sep, 2022
- 1 location
Botulism Prevention
A Phase 2, multicenter, randomized, double-blinded, placebo-controlled study to evaluate repeat dose (50 mg and 100 mg) of G03-52-01 administered by IM injection(s) in adult subjects
- 13 views
- 12 Dec, 2022
- 1 location